ATRA Stock Analysis: Buy, Sell, or Hold?
ATRA - Atara Biotherapeutics, Inc
$4.34
-0.25 (-5.45%)
▼
5d:
-10.42%
30d:
-19.93%
90d:
-74.87%
WAIT
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 21, 2026
Get Alerted When ATRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ATRA is down 10.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ATRA is down 10.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ATRA is currently trading at $4.34, which is considered oversold relative to its 30-day fair value range of $4.46 to $5.94. From a valuation perspective, the stock is trading at a discount (Forward PE: -7.2) compared to its historical average (26.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ATRA is in a strong downtrend. The price is currently testing key support at $4.40. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ATRA is in a strong downtrend. The price is currently testing key support at $4.40. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$4.46 -
$5.94
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.4%)
- NEUTRAL: Near Wall St target ($5.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Recommendation downgraded due to -10.4% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$4.46 -
$5.94
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$4.40
Resistance Level
$5.74
Current Trend
Strong Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.23
Wall Street Target
$5.00
(+8.9%)
Revenue Growth (YoY)
-95.1%
Profit Margin
27.1%
PE vs Historical
-7.2 vs 26.5
CHEAP
Share & Embed Analysis
Last updated: March 30, 2026 2:52 PM ET
Data refreshes hourly during market hours. Next update: 3:52 PM
Data refreshes hourly during market hours. Next update: 3:52 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Innovation Ltd Panacea
SELL
80554 shares
2026-01-12
Anhco Nguyen
SELL
2915 shares
2025-11-17
Yanina Grant-Huerta
SELL
1804 shares
2025-11-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1018 | 61 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$132 | 48 HOLD |
